Intellia Therapeutics, Inc.
NTLA
$7.25
-$1.19-14.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -519.02M | -522.28M | -508.80M | -485.50M | -481.19M |
| Total Depreciation and Amortization | 10.29M | 10.19M | 9.87M | 9.44M | 8.98M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 147.98M | 142.41M | 136.33M | 115.93M | 130.58M |
| Change in Net Operating Assets | 11.88M | 12.95M | -10.68M | -45.28M | -52.45M |
| Cash from Operations | -348.88M | -356.74M | -373.28M | -405.42M | -394.09M |
| Capital Expenditure | -5.78M | -6.32M | -9.37M | -12.66M | -13.99M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.35M | 26.26M | 116.52M | 109.46M | -17.36M |
| Cash from Investing | 125.57M | 19.94M | 107.15M | 96.80M | -31.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 185.75M | 289.91M | 226.82M | 188.09M | 130.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 185.75M | 289.91M | 226.82M | 188.09M | 130.32M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.57M | -46.88M | -39.31M | -120.52M | -295.11M |